Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from ImmunoPrecise Antibodies ( (IPA) ) is now available.
On August 1, 2025, ImmunoPrecise Antibodies Ltd. announced details regarding its upcoming Annual General Meeting of Security Holders, scheduled for October 9, 2025. The meeting will be held virtually, with the record date for notice and voting set for August 27, 2025. This announcement is crucial for stakeholders as it outlines the procedural details for participation and voting, reflecting the company’s ongoing commitment to shareholder engagement and corporate governance.
The most recent analyst rating on (IPA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on ImmunoPrecise Antibodies stock, see the IPA Stock Forecast page.
Spark’s Take on IPA Stock
According to Spark, TipRanks’ AI Analyst, IPA is a Neutral.
ImmunoPrecise Antibodies’ overall stock score is primarily influenced by its financial performance challenges, despite positive technical indicators and a strong earnings call. The company’s revenue growth and strategic initiatives are promising, but ongoing profitability issues and valuation concerns pose significant risks.
To see Spark’s full report on IPA stock, click here.
More about ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd. operates in the biotechnology industry, focusing on the development and commercialization of therapeutic antibodies. The company provides a range of services including custom antibody discovery and development, catering to pharmaceutical and biotech companies globally.
Average Trading Volume: 2,438,135
Technical Sentiment Signal: Buy
Current Market Cap: $76.62M
For an in-depth examination of IPA stock, go to TipRanks’ Overview page.